These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10454977)

  • 1. Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial.
    Szucs TD; Meyer BJ; Kiowski W
    Eur Heart J; 1999 Sep; 20(17):1253-60. PubMed ID: 10454977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
    Huynh T; Theroux P; Snapinn S; Wan Y;
    Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study].
    Szucs TD; Schwenkglenks M; Berger K; Karsch K
    Z Kardiol; 2003 Mar; 92(3):236-44. PubMed ID: 12658471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
    Okmen E; Cakmak M; Tartan Z; Cam N
    Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants.
    Gianetti J; Gensini G; De Caterina R
    Thromb Haemost; 1998 Dec; 80(6):887-93. PubMed ID: 9869155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet glycoprotein inhibitors in patients with medically managed acute coronary syndrome: does the enthusiasm exceed the science?
    Schriger DL; Herbert ME
    Ann Emerg Med; 2001 Sep; 38(3):249-55. PubMed ID: 11524643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial.
    Servoss SJ; Wan Y; Snapinn SM; DiBattiste PM; Zhao XQ; Theroux P; Jang IK; Januzzi JL;
    Am J Cardiol; 2004 Apr; 93(7):843-7. PubMed ID: 15050486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.
    Morrow DA; Antman EM; Snapinn SM; McCabe CH; Theroux P; Braunwald E
    Eur Heart J; 2002 Feb; 23(3):223-9. PubMed ID: 11792137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating cost-effectiveness evidence into clinical practice guidelines in Australia for acute myocardial infarction.
    Antioch KM; Jennings G; Botti M; Chapman R; Wulfsohn V
    Eur J Health Econ; 2002; 3(1):26-39. PubMed ID: 15609115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eptifibatide and tirofiban: new preparations. Limited benefit.
    Prescrire Int; 2000 Oct; 9(49):135-8. PubMed ID: 11603412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom.
    Bakhai A; Flather MD; Collinson JR; Stevens W; Normand C; Alemao E; Itzler R; Ben-Joseph R
    Int J Cardiol; 2003 Oct; 91(2-3):163-72. PubMed ID: 14559126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effective treatment of acute coronary syndromes-IIB or not IIB?
    Klein WW
    Eur Heart J; 1999 Sep; 20(17):1217-9. PubMed ID: 10454971
    [No Abstract]   [Full Text] [Related]  

  • 13. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction.
    Mahoney EM; Jurkovitz CT; Chu H; Becker ER; Culler S; Kosinski AS; Robertson DH; Alexander C; Nag S; Cook JR; Demopoulos LA; DiBattiste PM; Cannon CP; Weintraub WS;
    JAMA; 2002 Oct; 288(15):1851-8. PubMed ID: 12377083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of tirofiban in acute coronary syndromes.
    Gomma A; Collinson J; Purcell H; Flather M
    Int J Clin Pract; 2000 Mar; 54(2):121-4. PubMed ID: 10824369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
    Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
    Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).
    Morrow DA; Sabatine MS; Antman EM; Cannon CP; Braunwald E; Theroux P
    Am J Cardiol; 2004 Sep; 94(6):774-6. PubMed ID: 15374786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study.
    Huynh T; Piazza N; DiBattiste PM; Snapinn SM; Wan Y; Pharand C; Theroux P
    Int J Cardiol; 2005 Apr; 100(1):73-8. PubMed ID: 15820288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P; Stenestrand U; Malmberg K; Jönsson B
    Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial.
    Lindgren P; Jönsson B; Yusuf S
    J Intern Med; 2004 May; 255(5):562-70. PubMed ID: 15078498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.